Analysis of single-center clinical trial results for the novel Memoclip transapical mitral valve clip system

HUANG Jian-bing; ZENG Fan-qiang; TANG Min; JIANG Zhao-lei; ZHOU Chang-ping; LIU Hai-xia; ZHANG Li; DING Fang-bao; MEI Ju

doi:10.3969/j.issn.1672-5301.2025.04.004

Abstract：Objective To summarize the clinical data of patients with mitral regurgitation treated by the novel Memoclip transapical mitral valve clip system.And to explore the design features,safety and efficacy of the Memoclip system.Methods A total of 49 mitral regurgitation patients[24(49.0％)males,25(51％)females;age(68±12.8)years]treated by the novel Memoclip system from December 2021 to August 2023 were included.Preoperative transesophageal echocardiography(TEE)confirmed severe mitral regurgitation(grade 3+or higher)in all patients,classified as Type Ⅰ(n=30,61.2％),Type Ⅱ(n=11,22.4％),Type Ⅲb(n=4,8.2％),and Type Ⅳ(n=4,8.2％).All patients underwent transapical edge-to-edge mitral valve clipping under ultrasound guidance.Transesophageal echocardiography would assess the mitral regurgitation grade immediately after surgery.Postoperative follow-up at 1,3,6,and 12 months included echocardiography,cardiac function status,6-minute walking distance,and quality of life scores.Results No perioperative deaths occurred.Intraoperative TEE showed satisfactory results of mitral valve repair,with residual mitral regurgitation≤ 1+in 48 cases and 2+in 1 case.During follow-up,mitral regurgitation increased to 2+in 12 patients,3+in 1 patient,and transient 3+(reduced to 1+after medical therapy)in 1 patient.One patient showed worsened 6-minute walking distance and quality of life scores without functional improvement,while others exhibited significant improvements in 6-minute walking distance,quality of life,and cardiac function.Conclusion The novel Memoclip transapical mitral valve clip system is safe and effective for anatomically suitable mitral regurgitation patients,achieving significant regurgitation reduction and satisfactory therapeutic outcomes.